These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9209216)

  • 21. [Visceral leishmaniasis and HIV infection in the HAART era].
    Marques N; Cabral S; Sá R; Coelho F; Oliveira J; Saraiva da Cunha JG; Meliço Silvestre A
    Acta Med Port; 2007; 20(4):291-8. PubMed ID: 18198072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous leishmaniasis associated with visceral leishmaniasis in a case of acquired immunodeficiency syndrome (AIDS).
    Pourahmad M; Hooshmand F; Rahiminejad M
    Int J Dermatol; 2009 Jan; 48(1):59-61. PubMed ID: 19126052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intestinal parasitic infections and leishmaniasis in patients with HIV infection].
    Moreno-Camacho A; López-Vélez R; Muñoz Sanz A; Labarga-Echevarría P
    Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():52-60. PubMed ID: 9859620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engima of therapeutic failure in visceral leishmaniasis.
    Arya SC
    J Assoc Physicians India; 1993 Mar; 41(3):155-8. PubMed ID: 8226600
    [No Abstract]   [Full Text] [Related]  

  • 25. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
    Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
    Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.
    Diro E; Edwards T; Ritmeijer K; Fikre H; Abongomera C; Kibret A; Bardonneau C; Soipei P; Mutinda B; Omollo R; van Griensven J; Zijlstra EE; Wasunna M; Alves F; Alvar J; Hailu A; Alexander N; Blesson S
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007132. PubMed ID: 30789910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection].
    Delgado Fernández M; García Ordoñez MA; Martos Pérez F; Reguera Iglesias JM; Jiménez Oñate F; Colmenero Castillo JD
    An Med Interna; 1997 Oct; 14(10):506-10. PubMed ID: 9424140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leishmaniasis in HIV-infected persons: a review.
    Paredes R; Laguna F; Clotet B
    J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):22-39. PubMed ID: 11364428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal Amphotericin B drug access for the treatment of leishmaniasis in Brazil.
    Mistro S; Rodrigues M; Rosa L; Camargo M; Badaró R
    Trop Med Int Health; 2016 Jun; 21(6):692-3. PubMed ID: 27037644
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; van Loen H; Tsoumanis A; Adriaensen W; Hailu A; Griensven JV
    Clin Infect Dis; 2018 Jan; 66(3):444-451. PubMed ID: 29020217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine.
    Lustig V; Kager PA; Meenhorst PL
    Neth J Med; 1995 Aug; 47(2):66-9. PubMed ID: 7566284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
    Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
    Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kala Azar and HIV.
    Shahi SK; Ranga S; Khurana SK; Talib VH
    Indian J Pathol Microbiol; 1998 Jul; 41(3):269-70. PubMed ID: 9805846
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment and primary and secondary prevention of cerebral toxoplasmosis in patients with HIV infection].
    Podzamczer D
    Enferm Infecc Microbiol Clin; 1994 Mar; 12(3):158-63. PubMed ID: 8011724
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical survey of Leishmania/HIV co-infection in Catania, Italy: the impact of highly active antiretroviral therapy (HAART).
    Russo R; Nigro L; Panarello G; Montineri A
    Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():149-55. PubMed ID: 14678642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Visceral leishmaniasis: clinical sensitivity and resistance to various therapeutic agents].
    Janvier F; Morillon M; Olliaro P
    Med Trop (Mars); 2008 Feb; 68(1):89-101. PubMed ID: 18478781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges in the management of visceral leishmaniasis.
    Sundar S; Kumar A
    Indian Pediatr; 2005 Jun; 42(6):523-6. PubMed ID: 15995268
    [No Abstract]   [Full Text] [Related]  

  • 39. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.